What an FDA Inspection Could Look Like for Cannabis: Are You Read

While nobody knows exactly what future federal oversight will look like, the FDA's existing inspection model offers a clear roadmap for cannabis operators today.

For years, cannabis operators have asked the same question: "What happens if the FDA gets involved?"

It's a fair question. As discussions around Schedule III, federal reform, and national cannabis policy continue, many businesses are trying to picture what future oversight might actually look like.

Here's the truth: nobody knows exactly how federal cannabis regulation will evolve. But we do know something important the FDA already regulates thousands of facilities across the country, and their inspection approach follows predictable principles.

For operators paying attention, those principles offer a valuable preview of what cannabis oversight could resemble. The good news is that the roadmap is already visible.

FDA Inspectors Don't Just Look at Products

One of the biggest misconceptions about FDA inspections is that inspectors focus primarily on products. In reality, FDA inspections focus heavily on systems.

Inspectors often ask questions like:

The FDA isn't simply evaluating what happened today, they're evaluating whether the system can consistently produce acceptable outcomes tomorrow.

The First Thing They May Ask For

In many regulated industries, one of the first requests is surprisingly simple: "Show us your SOPs."

Why? Because SOPs reveal how the organization claims it operates. Inspectors may review:

The goal isn't simply to verify that SOPs exist, it's to determine whether the business actually follows them.

Training Records Would Likely Matter

An FDA inspector may ask: "How do you know your employees are qualified?"

That question often leads directly to training records, including:

A common regulatory principle applies here: if training isn't documented, it may be treated as if it never occurred. Documentation becomes evidence.

Document Control Could Become a Major Focus

Many cannabis businesses operate with multiple SOP versions, outdated forms, inconsistent records, and uncontrolled documents. FDA-regulated industries typically require much tighter control.

Inspectors may evaluate document approval processes, revision history, version control, and whether employees have access to the current procedure. One question often comes down to: "How do you ensure employees are using the correct procedure?"

Traceability Will Likely Be Critical

One area where cannabis operators may already have an advantage is traceability — most state systems already require tracking. However, FDA expectations often extend well beyond inventory tracking.

Inspectors may want to understand raw material sourcing, supplier qualification, batch history, processing records, and distribution records. A common question might be: "Can you trace this product from origin to final sale?" And just as importantly: "How quickly can you do it?"

CAPA Systems Could Receive Significant Attention

One of the most important indicators of operational maturity is how a company responds when something goes wrong.

FDA inspectors frequently evaluate deviations, complaints, nonconformances, investigations, and corrective actions. They may ask:

Companies that can't answer those questions often struggle during inspections.

Internal Audits Demonstrate Accountability

An FDA inspector may ask a simple question: "How do you know your systems are working?"

One answer is internal auditing, it demonstrates that the organization actively evaluates itself. Inspectors often view strong audit programs as evidence of management involvement, continuous improvement, and operational oversight. A business that never audits itself may appear reactive rather than proactive.

Equipment and Maintenance Records Matter

Cannabis facilities increasingly rely on sophisticated equipment, HVAC systems, extraction equipment, irrigation systems, packaging equipment, and environmental controls.

Inspectors may review maintenance schedules, calibration records, service reports, and equipment logs. The underlying question: "Can you demonstrate this equipment performs as intended?"

Supplier Qualification Could Become a Bigger Issue

FDA-regulated industries often place significant emphasis on suppliers. Future cannabis oversight could include questions such as:

Many cannabis businesses currently focus on price and availability. Future expectations may focus more heavily on documented supplier management.

The Inspection May Focus on Leadership

One surprise for many operators is that inspections often extend well beyond front-line employees. Inspectors frequently evaluate leadership involvement, asking:

The FDA often expects quality to be a leadership responsibility — not merely a compliance department function.

Data Integrity May Become a Major Theme

One phrase frequently heard in FDA inspections is "data integrity." In simple terms: can the company trust its own records?

Inspectors may evaluate record accuracy, data retention, audit trails, documentation practices, and record corrections. The expectation is straightforward, records should be complete, accurate, and trustworthy.

What an FDA Inspector Might Ask

Imagine an inspector pulls a finished cannabis product from inventory and asks:

Could your team retrieve that information quickly? That question may be one of the best measures of readiness.

The Businesses Most Likely to Succeed

If future cannabis oversight follows patterns seen across food, dietary supplements, pharmaceuticals, and medical devices, the operators best positioned will likely have:

In other words: strong systems, not just good intentions.

The Time to Prepare Is Before the Inspector Arrives

The most successful FDA inspections begin long before the inspector ever shows up. Preparation is built through documentation, accountability, consistency, training, and continuous improvement.

Businesses that build these capabilities today may find future regulatory transitions far less disruptive. Those that wait may face a much steeper learning curve.

The Future May Reward Operational Maturity

Nobody knows exactly what federal cannabis oversight will look like. But we do know what regulators value: consistency, traceability, accountability, documentation, risk management, and quality systems. Those principles are unlikely to change.

The cannabis businesses that begin building around them now may be best positioned for whatever comes next.

At Red Wolf Risk, we help cannabis operators prepare for future regulatory expectations through Quality Management Systems, CAPA programs, audit readiness, GMP preparation, risk management, and federal readiness assessments.

The best FDA inspection is the one you're already prepared for before it happens.

Alex Hearding is the Founder and President of Red Wolf Risk and has more than 17 years of experience in cannabis operations, risk management, quality systems, and regulatory compliance.